Role of the VEGF/VEGFR pathways in the development, progression, and treatment of cholangiocellular carcinoma / 临床肝胆病杂志

ABSTRACT

Cholangiocellular carcinoma (CCA) is a malignant tumor derived from the biliary epithelium, with a lack of effective therapeutic drugs and poor prognosis. Studies have shown that the development and progression of CCA are closely associated with angiogenesis, and a variety of angiogenic factors, including vascular endothelial growth factor (VEGF) and its receptor VEGFR, can regulate angiogenesis in CCA, participate in the development and progression of CCA, and affect its prognosis. Therefore, anti-angiogenic drugs targeting VEGF/VEGFR, such as monoclonal antibodies and small-molecule inhibitors, have gradually become research hotspots for the treatment of CCA. This article reviews the role of the VEGF/VEGFR pathways in the clinical features and prognosis of CCA, the advances in anti-angiogenic therapy for CCA, and related studies on drug resistance.